Tech Company Financing Transactions
eGenesis Funding Round
eGenesis closed a $191 million Series B investment round on 9/4/2024. Investors included Lux Capital, Alta Partners and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
9/4/2024
Transaction Type
Venture Equity
Amount
$191,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its lead product candidate, EGEN-2784, to a first-in-human study for transplant.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Technology Sq. 301
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
eGenesis is a life sciences company focused on leveraging CRISPR technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Sekhri
Chief Operating Officer
Peter Hanson
VP - Bus. Development
Jennifer Bergheiser
VP - Bus. Development
Ariel Jasie
VP - Human Resources
Elizabeth Roberts
VP - R & D
Michael Curtis
VP - Regulatory Affairs
David Carmel
Browse more venture capital transactions:
Prev: 9/4/2024: Reduced venture capital transaction
Next: 9/4/2024: Hepta Medical venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs